Table 2 Baseline characteristics and adjusted hazard ratios of four-month survival in the cohort (n = 633)

Overall survival, months

4 [1; 11]

Length of stay in the hospital (days)

11 [6; 20]

Performance status at the first case presentation

in multidisciplinary concertation meetings*

PS 0–1

212 (53.1)

PS 2

126 (31.6)

PS 3–4

61 (15.3)

Men

540 (71.0)

1.3 [1.0; 1.6]

0.07

1.3 [1.0; 1.7]

0.03

Metastasis

428 (74.2)

2.0 [1.5; 2.6]

< 0.01

1.9 [1.3; 2.9]

< 0.01

Histological type

< 0.01

Adenocarcinoma

295 (46.6)

1

1

Squamous-cell carcinoma

103 (16.3)

0.9 [0.6; 1.2]

0.40

1.0 [0.7; 1.4]

0.87

Undifferentiated carcinoma

67 (10.6)

0.4 [1.2; 0.8]

0.40

1.2 [0.8; 1.7]

0.33

Small-cell lung cancer

132 (20.9)

0.7 [0.5; 0.9]

< 0.01

0.7 [0.5; 0.9]

< 0.01

Other types

36 (5.7)

1.9 [1.2; 2.8]

< 0.01

1.9 [1.3; 2.9]

< 0.01

Age during hospitalization

66 [58;73]

1.1 [0.9; 1.3]

0.54

Age at diagnostic

65 [58;72]

1.1 [0.9; 1.3]

0.60

Time of cancer diagnosis

Diagnosis before hospitalization

518 (81.8)

1

Diagnosis during or after hospitalization

115 (18.2)

0.9 [0.7; 1.2]

0.47